Company facts
- Industry
- Pharmaceutical Preparations
- Headquarters
- South San Francisco, California
- Most recent report
- 10-Q, filed Nov 3, 2026
- Incorporated
- Delaware
- Filings on record
- 506 filings
- On EDGAR
- CIK 1676725
- Fiscal year ends
- December
- Filer status
- Large accelerated filer
Financials 8 of 31
News 8 of 106
Prospectuses and Registrations 8 of 39
- S-8 Registration statement for an employee plan Nov 3, 2026
- 424B5 Prospectus supplement for an offering Jun 9, 2026
- 424B5 Prospectus supplement for an offering Jun 8, 2026
- 424B5 Prospectus supplement for an offering May 5, 2026
- S-3ASR Automatic shelf registration May 5, 2026
- S-8 Registration statement for an employee plan Feb 17, 2026
- S-8 Registration statement for an employee plan Aug 5, 2025
- S-8 Registration statement for an employee plan Feb 18, 2025
Proxies 8
- DEFA14A Extra proxy material Apr 30, 2026
- DEF 14A Proxy statement for a shareholder vote Apr 29, 2026
- DEF 14A Proxy statement for a shareholder vote Apr 30, 2025
- DEF 14A Proxy statement for a shareholder vote Apr 19, 2024
- DEF 14A Proxy statement for a shareholder vote Apr 14, 2023
- DEF 14A Proxy statement for a shareholder vote Apr 26, 2022
- DEF 14A Proxy statement for a shareholder vote Apr 19, 2021
- DEF 14A Proxy statement for a shareholder vote Apr 27, 2020
Ownership 8 of 291
- 4 Insider reported a trade Oct 8, 2026
- 144 Notice of a proposed sale of restricted stock Oct 6, 2026
- SCHEDULE 13G Large holder reported a passive stake Aug 14, 2026
- SCHEDULE 13G Large holder reported a passive stake Jul 31, 2026
- 4 Insider reported a trade Jul 9, 2026
- 144 Notice of a proposed sale of restricted stock Jul 7, 2026
- 4 Insider reported a trade Jun 18, 2026
- 4 Insider reported a trade Jun 18, 2026
Other 8 of 31
- ARS Annual report sent to shareholders Apr 29, 2026
- ARS Annual report sent to shareholders May 20, 2025
- ARS Annual report sent to shareholders Apr 24, 2024
- ARS Annual report sent to shareholders May 15, 2023
- EFFECT Notice that a registration became effective Apr 20, 2021
- CORRESP Reply to SEC staff Apr 16, 2021
- UPLOAD Comment letter from SEC staff Mar 25, 2021
- SEC STAFF LETTER Mar 23, 2021
Everything here comes from IDEAYA Biosciences, Inc.'s own filings on SEC EDGAR. The filing list is rechecked every hour.